WO2001028566B1 - Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia - Google Patents

Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Info

Publication number
WO2001028566B1
WO2001028566B1 PCT/GB2000/004029 GB0004029W WO0128566B1 WO 2001028566 B1 WO2001028566 B1 WO 2001028566B1 GB 0004029 W GB0004029 W GB 0004029W WO 0128566 B1 WO0128566 B1 WO 0128566B1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
acetylsalicylic acid
benign prostate
prostate hyperplasia
acid
Prior art date
Application number
PCT/GB2000/004029
Other languages
French (fr)
Other versions
WO2001028566A1 (en
Inventor
Marcial Lopez Lopez
Maria Jose Montero Gomez
Maria Angeles Sevilla Toral
Arturo San Feliciano
Original Assignee
Inst Helmaprost Sl
Ruffles Graham Keith
Marcial Lopez Lopez
Maria Jose Montero Gomez
Maria Angeles Sevilla Toral
Arturo San Feliciano
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Helmaprost Sl, Ruffles Graham Keith, Marcial Lopez Lopez, Maria Jose Montero Gomez, Maria Angeles Sevilla Toral, Arturo San Feliciano filed Critical Inst Helmaprost Sl
Priority to AU10367/01A priority Critical patent/AU1036701A/en
Publication of WO2001028566A1 publication Critical patent/WO2001028566A1/en
Publication of WO2001028566B1 publication Critical patent/WO2001028566B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aspirin is of use in the treatment of benign prostate hyperplasia.

Claims

AMENDED CLAIMS[received by the International Bureau on 09 May 2001 (09.05.01); original claim 1 amended; original claim 7 cancelled; original claims 8 and 9 amended and renumbered as claims 7 and 8 remaining claims unchanged (1 page)]
1. A method of treatment of the symptoms of benign prostate hyperplasia by relaxation of prostate tissue which involves administering an effective amount of acetylsalicylic acid.
2. A method according to claim 1, wherein the drug is given once or twice a day.
3. A method according to claim 1 or 2, wherein the dose is in the range 50 to 400 mg acetylsalicylic acid.
4. A method according to claim 3, wherein the dose is in the range 80 to 325 mg acetylsalicylic acid.
5. A method according to claim 4, wherein the dose is 100 or 200 or 300 or 325 mg acetylsalicylic acid.
6. A method according to any preceding claim, wherein the drug is administered as one or more tablets.
7. A pharmaceutical composition of acetylsalicylic acid and a pharmaceutically acceptable carrier for use in the treatment of the symptoms of benign prostate hyperplasia by relaxation of prostate tissue.
8. The use of acetylsalicylic acid in the preparation of a pharmaceutical composition for treatment of the symptoms of benign prostate hyperplasia by relaxation of prostate tissue.
PCT/GB2000/004029 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia WO2001028566A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU10367/01A AU1036701A (en) 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924766.0A GB9924766D0 (en) 1999-10-19 1999-10-19 New use of acetyl salicilic acid
GB9924766.0 1999-10-19

Publications (2)

Publication Number Publication Date
WO2001028566A1 WO2001028566A1 (en) 2001-04-26
WO2001028566B1 true WO2001028566B1 (en) 2001-10-11

Family

ID=10863019

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004029 WO2001028566A1 (en) 1999-10-19 2000-10-19 Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia

Country Status (3)

Country Link
AU (1) AU1036701A (en)
GB (1) GB9924766D0 (en)
WO (1) WO2001028566A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385240B1 (en) * 2010-07-26 2013-09-23 Gp-Pharm, S.A. CAPSULES OF ACTIVE PHARMACEUTICAL PRINCIPLES AND POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF PROSTATE DISEASES.
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437838A1 (en) * 1978-07-25 1980-04-30 Roecar Holdings Nv Prostaglandin inhibitors for benign adenoma of the prostate - includes salicylic, anthranilic and phenylacetic acid derivs., indole(s), indene(s), pyrrole(s) and pyrazolidine(s)
EP0372676A1 (en) * 1988-12-08 1990-06-13 Spyros Carantinos Therapeutic preparation and method
GB2306109B (en) * 1997-02-07 1997-09-24 John Wright A zinc containing composition as a common cold prophylactic

Also Published As

Publication number Publication date
GB9924766D0 (en) 1999-12-22
WO2001028566A1 (en) 2001-04-26
AU1036701A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AU1227899A (en) Osmotic medicament releasing system
CA2070061A1 (en) Physiologically active polypeptide-containing pharmaceutical composition
NZ508526A (en) Opioid formulations for treating pain
IL139231A0 (en) Preparations for the application of anti-inflammatory, especially antiseptic, agents and/or agents promoting the healing of wounds to the lower respiratory tract
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
KR930007441A (en) medicine
CA2175429A1 (en) Pharmaceutical compositions and methods
CA2387486A1 (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
JP2006516571A5 (en)
CA2559239A1 (en) Use of simethicone and sodium picosulphate in constipated patients suffering from bloated feeling and gas discomfort during the night
RU95101385A (en) Products containing g-csf and tnf-binding protein
AR035946A1 (en) PHARMACEUTICAL COMPOSITIONS TO USE IN THE TREATMENT OF DISORDERS IN WOMEN PERIMENOPAUSIC, MENOPAUSIC OR POSMENOPAUSIC, AND USES OF SUCH COMPOSITIONS FOR THE PREPARATION OF MEDICINES
CA2447712A1 (en) Herbal drug composition for cartilage protection
WO2002064214A8 (en) Anti cancer combination of substituted pyrroles and paclitaxel
WO2001028566B1 (en) Use of acetyl salicilyc acid for the treatment of benign prostate hyperplasia
KR900011461A (en) Therapeutics using trypstatin as an active ingredient
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
KUFLIK Cryosurgical treatment of periungual warts
AU2001289762A1 (en) Pharmaceutical extemporary compositions
EA199700025A1 (en) APPLICATION OF OLIGOSACCHARIDE AND ASPIRIN TO PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
WO2001001995A3 (en) Method for treatment of asthma syndrome
AU4633197A (en) Pharmaceutical composition comprising a combination of isosorbide nitrate with acetylsalicylic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP